

National Adult Immunisation Schedule (NAIS)
(for persons age 18 years or older)

Vaccine	18-26 years	27-59 years	60-64 years	≥ 65 years
Influenza (INF)	1 dose annually or per season			1 dose annually or per season
Pneumococcal: • PCV20; <u>or</u> • PCV13 and/or PPSV23	1 dose of PCV20; <u>or</u> 1 dose of PCV13 and/or 1 or more doses of PPSV23, depending on age			or medical condition(s)
Shingles: Recombinant herpes zoster vaccine (RHZV)	2 doses			
COVID-19	1 initial dose (3 doses for immunocompromised), followed by 1 dose annually			
Tetanus, reduced diphtheria and acellular pertussis (Tdap)	1 dose during each pregnancy			
Human papillomavirus (HPV2)	3 doses (Females)			
Hepatitis B (HepB)	3 doses (4 doses for adults with renal insufficiency)			
Measles, mumps and rubella (MMR)	2 doses			
Varicella (VAR)	2 doses			

	Recommended for persons who meet age requirements
	Recommended for persons with specific medical condition or indication
	Recommended for persons who have not been previously vaccinated, or lack evidence of past infection or immunity

Details of the vaccinations recommended under the NAIS

Note: Individuals or caregivers should consult a doctor for vaccination advice specific to the individual's age and medical condition(s), as well as eligibility for subsidised vaccination.

Recommended Vaccine Types, Doses and Groups in the NAIS – Influenza Vaccine		
Vaccine	Recommendations	Additional information
Influenza (INF)	• Seasonal influenza vaccine is recommended for persons age 18 years or older who are at increased risk of influenza-related complications. • Vaccination is recommended annually or per season, depending on the prevailing recommendations for vaccination that year.	High-risk groups recommended for seasonal influenza vaccination - Persons age 65 years or older • Recommended for all persons - Persons age 18 years or older with any of the following conditions: • who have chronic disorders of the pulmonary or cardiovascular systems, including asthma • who have required medical follow-up or hospitalisation due to chronic metabolic diseases (including diabetes mellitus), renal, neurologic, hepatic, or haematologic disorders, or immunosuppression (including immunosuppression caused by medications, HIV or other immunodeficiencies) - Other recommended groups • Persons age 18 years who are receiving long term aspirin therapy and therefore might be at risk for developing Reye syndrome after influenza infection • Women at all stages of pregnancy • Persons receiving intermediate and long-term care (ILTC) services

Recommended Vaccine Types, Doses and Groups in the NAIS – Pneumococcal Vaccines		
Vaccine	Recommendations	Additional information
Pneumococcal vaccine (summary)	- For persons who are recommended for pneumococcal vaccination who have: - not previously received any pneumococcal vaccine can either receive: ○ PCV20; or ○ PCV13 and/or PPSV23 as per prevailing recommendations. - received PCV13 and/or PPSV23 but not completed the recommended vaccination series can either: ○ receive PCV20 to complete the vaccination series; or ○ complete the vaccination series as per prevailing recommendations using PCV13 and/or PPSV23.	Refer to subsequent rows for recommendations specific to PCV20, PCV13 and PPSV23
20-valent Pneumococcal conjugate vaccine (PCV20)	- PCV20 is recommended for persons aged 18 years or older who are at increased risk of developing severe pneumococcal disease Recommended dose - Only one dose of PCV20 is recommended regardless of age or conditions as listed in the high-risk groups	High-risk groups recommended for PCV20 - Persons age 65 years or older - Recommended for all persons - Persons age 18 years or older with any of the following conditions: - Chronic medical conditions, comprising: ○ Chronic pulmonary disease ○ Chronic cardiovascular disease ○ Chronic liver disease ○ Diabetes mellitus - Cochlear implants or cerebrospinal fluid leaks; - Immunocompromising conditions; - Chronic kidney disease.
13-valent Pneumococcal conjugate vaccine (PCV13)	- PCV13 is recommended for persons age 18 years or older who are at increased risk of developing severe pneumococcal disease Recommended dose and interval - Only one dose of PCV13 is recommended regardless of age or conditions as listed in the high-risk groups - If both PCV13 and PPSV23 are indicated, PCV13 should be given first, and PPSV23 administered at the appropriate interval later - If PCV20 is preferred to complete the vaccination series, please consult a doctor for vaccination advice on individual's suitability to do so.	High-risk groups recommended for PCV13 - Persons age 65 years or older - Recommended for all persons - Persons age 18 years or older with any of the following conditions: - Cochlear implant or cerebrospinal fluid leaks; - Immunocompromising conditions; - Chronic kidney disease.

Recommended Vaccine Types, Doses and Groups in the NAIS – Pneumococcal Vaccines		
Vaccine	Recommendations	Additional information
Pneumococcal polysaccharide (PPSV23)	- PPSV23 is recommended for persons age 18 years or older who are at increased risk of developing severe pneumococcal disease Recommended doses and interval - One or two doses of PPSV23 are recommended depending on age or conditions as listed in the high-risk groups - If both PCV13 and PPSV23 are indicated, PCV13 should be given first, and PPSV23 administered at the appropriate interval later - If PCV20 is preferred to complete the vaccination series, please consult a doctor for vaccination advice on individual's suitability to do so.	High-risk groups recommended for PPSV23 Persons age 65 years or older - Recommended for all persons Persons age 18 years or older with any of the following conditions: - Chronic medical conditions, comprising: - Chronic pulmonary disease - Chronic cardiovascular disease - Chronic liver disease - Diabetes mellitus - Cochlear implants or cerebrospinal fluid leaks; - Immunocompromising conditions; - Chronic kidney disease.

Recommended Vaccine Types, Doses and Groups in the NAIS – RHZV		
Vaccine	Recommendations	Additional information
Recombinant herpes zoster vaccine (RHZV)	- RHZV is recommended for persons aged 18 years or older who are at increased risk of developing shingles and associated complications Recommended doses and interval Persons age 60 years or older - Two doses are recommended at an interval of 2-6 months Persons age 18 years or older with immunocompromising conditions - Two doses are recommended. The interval can be shorter at 1-2 months if earlier protection is desired	High-risk groups recommended for RHZV Persons age 60 years or older - Recommended for all persons Persons age 18 years or older with any of the following immunocompromising conditions - Primary or acquired immunodeficiency - Iatrogenic immunosuppression <u>Other recommendations</u> Persons who have previously received live, attenuated herpes zoster vaccine (HZVL) - An interval of ≥5 years between HZVL and RHZV is recommended in general - Due to lower efficacy of HZVL in adults aged 70 years or older, a shorter interval of ≥12 months between HZVL and RHZV can be considered - A minimum interval of 8 weeks between HZVL and RHZV should be observed for all recommended age groups Persons without a history of previous varicella infection, serological evidence of immunity or varicella vaccination - Verification of varicella immunity prior to receiving RHZV is not recommended regardless of age or medical condition

Recommended Vaccine Types, Doses and Groups in the NAIS – COVID-19 Vaccine		
Vaccine	Recommendations	Additional information
COVID-19	- COVID-19 vaccine is recommended for persons aged 18 years and older who are at increased risk of developing severe COVID-19 disease. Recommended doses and interval 1 dose for individuals receiving COVID-19 vaccination for the first time; followed by 1 dose at around one year (and at least 5 months) from the last vaccine dose Three initial doses for immunocompromised - Persons with moderate to severe immunocompromised conditions are recommended to receive a total of three doses of the mRNA vaccines for their initial doses. <i>Recommended interval between doses</i> - Dose 2: eight weeks after first dose - Dose 3: eight weeks after second dose	High-risk groups recommended for COVID-19 vaccine - Persons age 60 years or older - Recommended for all persons - Persons age 18 years or older with any of the following conditions - Diabetes, heart conditions (such as heart failure, ischaemic heart disease, cardiomyopathy), chronic lung (including asthma), liver (including cirrhosis), neurologic (including stroke) conditions and kidney conditions at any stage (including dialysis) - Cancer on active treatment, blood conditions (such as thalassaemia and sickle cell anaemia), genetic or metabolic conditions (including Down's syndrome and cystic fibrosis), obesity (BMI ≥ 30) - Immunodeficiencies (including HIV infection), persons on non-cancer immunosuppressive treatment - Women at all stages of pregnancy - Other recommended groups - Residents of aged care facilities Immunocompromised groups recommended for three initial doses - Persons age 18 years or older with any of the following conditions - Transplant patients on immunosuppressive therapy, including solid organ and allogenic stem cell transplants - Cancer patients on active treatment with chemotherapy and immunosuppressive therapy, haematological cancers - Immunosuppressive treatment for non-cancer conditions, advanced or untreated HIV - End-stage kidney disease

Recommended Vaccine Types, Doses and Groups in the NAIS – Tdap, HPV, HepB, MMR, Varicella		
Vaccine	Recommendations	Additional information
Tdap	- Tdap is recommended during 16-32 weeks of each pregnancy for protection of infant against pertussis, regardless of the interval since the previous Td or Tdap vaccination. - Tdap is recommended with each pregnancy to provide maximal protection to every infant, including pregnancies which are closely spaced (e.g. <2 years).	- Tdap can also be considered for pregnant women after 32nd week of gestation during each pregnancy. Maternal vaccination may afford less protection for infants, but would potentially protect the mother from pertussis infection and thereby reduce the risk of exposure to her infant. - Both Adacel and Boostrix can be used in pregnant women.
HPV	Recommended vaccine type - HPV2 (Cervarix) Recommended doses for females age 18-26 years 3-dose series at 0, 1, 6 months - Minimum intervals between doses Dose 2: at least 4 weeks from dose 1 Dose 3: at least 20 weeks from dose 1 and 12 weeks from dose 2	If HPV vaccination is initiated but not completed by age 26 years or earlier, remaining dose(s) may be completed after age 26 years, as early as possible, but up to age 45 years.
HepB	- HepB is recommended for persons without evidence of immunity or prior disease. Recommended doses and interval <u>Adults aged 18 years or older without renal insufficiency</u> Three doses are recommended at an interval of 0, 1, and 6 months, at 20mcg per dose <i>Minimum intervals between doses</i> - D2: At least 4 weeks from D1 - D3: At least 16 weeks from D1 and 8 weeks from D2 <u>Adults aged 18 years or older with renal insufficiency</u> Four doses are recommended at an interval of 0, 1, 2 and 6 months, at 40mcg (2 x 20mcg) per dose <i>Minimum intervals between doses</i> - D2: At least 4 weeks from D1 - D3: At least 4 weeks from D2 - D4: At least 16 weeks from D3	Adults with renal insufficiency refer to patients with chronic kidney disease stage 4 or 5 (excluding stage 1, 2 and 3) and/or those on renal dialysis. For adults with renal insufficiency, the dosage is considered “double”, i.e. 40mcg each dose.

Recommended Vaccine Types, Doses and Groups in the NAIS – Tdap, HPV, HepB, MMR, Varicella		
Vaccine	Recommendations	Additional information
MMR	• MMR is recommended for persons without evidence of immunity or prior disease • 2-dose series at least 4 weeks apart	-
Varicella (VAR)	• VAR is recommended for persons without evidence of immunity or prior disease • 2-dose series 4-8 weeks apart	-